One Year, Open Label, Dose Escalation Long-term Safety Study in Multiple Sclerosis (MS) Subjects With Spasticity
Status:
Completed
Trial end date:
2015-01-01
Target enrollment:
Participant gender:
Summary
Clinical protocol OS440-3003 is a multicenter, open-label, non-randomized, uncontrolled, dose
escalation study to evaluate the safety and tolerability of Arbaclofen Extended Release
Tablets over 1 year in Multiple Sclerosis (MS) subjects with spasticity. All subjects in this
study will receive arbaclofen in the extended release tablet formulation.